InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.130 0.01 (7.14%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$17 Ceasing to be a substantial holder 12 Dec 2022 6:00PM $0.490 $0.130 fallen by 73.47%
$17 SRC Approves Commencement Of Fourth And Final Cohort Dosing 8 Dec 2022 9:39AM $0.495 $0.130 fallen by 73.74%
$17 Change of Director's Interest Notice 30 Nov 2022 8:18AM $0.555 $0.130 fallen by 76.58%
$17 Notification regarding unquoted securities - AGN 30 Nov 2022 8:17AM $0.555 $0.130 fallen by 76.58%
$17 Phase 1 Clinical Trial Progress Update 25 Nov 2022 8:20AM $0.540 $0.130 fallen by 75.93%
$17 AGM Presentation 25 Nov 2022 8:20AM $0.540 $0.130 fallen by 75.93%
$17 Results of Annual General Meeting 25 Nov 2022 8:20AM $0.540 $0.130 fallen by 75.93%
$17 Safety Review Committee Approves Third Cohort Commencement 18 Nov 2022 9:01AM $0.610 $0.130 fallen by 78.69%
$17 Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial 7 Nov 2022 8:21AM $0.610 $0.130 fallen by 78.69%
$17 Safety Review Committee Approves Second Cohort 2 Nov 2022 9:09AM $0.535 $0.130 fallen by 75.70%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2022 4:47PM $0.520 $0.130 fallen by 75%
$17 No Serious Safety Issues Observed in First Cohort 26 Oct 2022 8:14AM $0.500 $0.130 fallen by 74%
$17 Notice of Annual General Meeting/Proxy Form 21 Oct 2022 8:16AM $0.475 $0.130 fallen by 72.63%
$17 Investor Presentation 20 Oct 2022 8:08AM $0.475 $0.130 fallen by 72.63%
$17 First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007 17 Oct 2022 9:34AM $0.450 $0.130 fallen by 71.11%
$17 Argenica Receives $1.38m R&D Tax Incentive Cash Refund 4 Oct 2022 8:01AM $0.440 $0.130 fallen by 70.45%
$17 Further Positive Preclinical Results for ARG-007 In HIE 29 Sep 2022 9:11AM $0.460 $0.130 fallen by 71.74%
$17 Date of AGM and Closing Date for Director Nominations 16 Sep 2022 8:20AM $0.650 $0.130 fallen by 80%
$17 Phase 1 Clinical Trial Summary 8 Sep 2022 8:34AM $0.485 $0.130 fallen by 73.20%
$17 Argenica Receives Ethics Approval To Commence Phase 1 Trial 7 Sep 2022 8:11AM $0.480 $0.130 fallen by 72.92%
$17 Appendix 4G & Corporate Governance Statement 23 Aug 2022 6:26PM $0.500 $0.130 fallen by 74%
$17 Appendix 4E & Annual Report 30 June 2022 23 Aug 2022 6:23PM $0.500 $0.130 fallen by 74%
$17 Ethics Application Submitted for Phase 1 Trial 11 Aug 2022 9:16AM $0.450 $0.130 fallen by 71.11%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2022 7:55AM $0.430 $0.130 fallen by 69.77%
$17 Clinical Advisory Committee Appointment 11 Jul 2022 8:24AM $0.455 $0.130 fallen by 71.43%

201 - 225 of 297 results

Page 9 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.